Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain

Completed · Phase 4

Conditions studied: Interstitial Cystitis

In brief

Intranasal Ketorolac tromethamine has a potential role as a short term pain management tool for Interstitial Cystitis without the risk and undesirable effects of narcotics.

Key facts

Study ID

NCT02000401

Run by

Citrus Valley Medical Research, Inc.

People needed

15

Starts

2012-05-01

Expected to finish

2013-07-01

Last updated by the study team

2013-12-04

Who can join

Age: 18 and older, up to 64. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female Subject must be between the age eighteen (18) years and sixty four (64)
• Subject must weigh 110lbs (50kg) or greater
• Willing and able to provide an informed consent
• Diagnosed with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
• Symptoms of IC/PBS that are moderate to severe (intermittent or chronic) for ≥ three (3) months
• A cystoscopic examination under anesthesia with hydro-distention and photo documentation will have been performed at time of diagnosis with IC. Bladder biopsies will have been performed only if carcinoma is suspected. (see exclusion # 5.2.25 - hydrodistention must be performed greater than four (4) weeks prior to baseline visit) Note: at investigator discretion subject may included with only operative report
• At screening subject must have a score ≥ four (4) out of ten (10) On Visual Analogue Pain Scale (VAS Pain Scale)
• Subject must have a score on the O'Leary/Sant scale of at least a five (5) on the symptom index at screening
• Voids greater than eight (8) in a twenty four (24) hour period
• Nocturia of at least one (1) time during sleeping period
• Subject of child-bearing potential must test negative for pregnancy prior to treatment or provide documentation for having undergone the following: hysterectomy or tubal ligation. Subjects who are physiologically capable of becoming pregnant must voluntarily sign a pregnancy waiver included within the informed consent and agree not to become pregnant for the duration of the study and for thirty (30) days following the completion of study. If a subject becomes pregnant during the course of this study, the subject will inform the Principal Investigator within one (1) working day of learning of the pregnancy

You may not qualify if…

• Current treatment with or known allergy or sensitivity to all forms of ketorolac tromethamine, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) or Ethylenediaminetetraacetic acid (EDTA) NOTE: if at time of signing consent a subject is receiving a non-steroidal inflammatory drug they may washout for seven days prior to completing the screening visit
• Subject is currently receiving or having had prior IC/PBS focused therapy on less than three (3) months stable doses. i.e. oral Pentosan Polysulfate(PPS) (Elmiron®), Amitriptyline (Elavil®), oxychlorosene (Clorpactin®), dimethyl sulfoxide (RIMSO 50™), heparin or antihistamine NOTE: Antihistamine is allowable as added treatment during course of study if for treatment of diagnosed nasal/seasonal/environmental allergy (i.e treatment other than IC) , If a subject is receiving intravesical instillations of any kind at least a two day washout must be adhered to before screening is performed. The subject must abstain from any intravesical instillation during the study.
• Current use of TENS (Transcutaneous Electrical Nerve Stimulation) or Interstim unit
• Clinically significant urinary tract infection (UTI) NOTE: dipstick urinalysis is done at screening urine culture will be performed if indicated by results of dipstick urinalysis at screening
• As needed Use of narcotics/opiate within one (1) week prior to the screening visit and entire study participation by self-reporting (Note: once subject has qualified they will be given the option of rescue medication for pain not relieved by the study medication)
• Use of illegal drugs by self-reporting
• History of drug or alcohol abuse within five (5) years of screening visit
• History of suicide attempt or suicidal thoughts by self-reporting within five (5) years of screening visit
• Any active co-morbid pelvic diagnosis (i.e. endometriosis, Irritable Bowel Syndrome, etc.) for which the subject is unable to distinguish between IC/PBS pain and pain from any other condition as determined by the investigator
• A diagnosis of a severe neuro-psychiatric disease
• Subject demonstrates an absence of nocturia
• Subject's frequency of urination is equal to or less than eight (8) times in a twenty four (24) hour period.
• Subject's symptoms relieved by antimicrobials, urinary antiseptics, anticholinergics, or antispasmodics.
• Subject has recurrent bladder or lower urethral calculi (recurrent is defined as > to 3 times in a 12 month period)
• Subject has active genital herpes with a (3) three month period of the screening visit
• Subject has uterine, cervical, vaginal, or urethral cancer
• Subject has been administered cyclophosphamide or any agent that causes chemical cystitis
• Subject has tubercular cystitis
• Subject has radiation cystitis
• Subject has benign or malignant bladder tumor
• Subject has a positive pathologic vaginal culture within three (3) months of the screening visit
• Subject has evidence of vesicle ureteral reflux or urethral diverticula
• Subject has neurogenic bladder dysfunction
• Subject has a prior urinary diversion
• Subject who is currently receiving investigational drug(s) or participated in a clinical trial involving investigational drug(s) within thirty (30) day of the screening visit

Where it is running

• Citrus Valley Medical Research, Inc — Glendora, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.